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Abstract
Purpose: The rationale of the present study was to radiolabel rituximab with 99m-technetium and
to image B lymphocytes infiltration in the affected tissues of patients with chronic inflammatory
autoimmune diseases, in particular, the candidates to be treated with unlabelled rituximab, in
order to provide a rationale for ‘evidence-based’ therapy.
Procedures: Rituximab was labelled with 99mTc via 2-ME reduction method. In vitro quality
controls of 99mTc-rituximab included stability assay, cysteine challenge, SDS-PAGE, immuno-
reactive fraction assay and competitive binding assay on CD20+ve Burkitt lymphoma-derived
cells. For the human pilot study, 350–370 MBq (100 μg) of 99mTc-rituximab were injected in 20
patients with different chronic inflammatory autoimmune diseases. Whole body anteroposterior
planar scintigraphic images were acquired 6 and 20 h p.i.
Results: Rituximab was labelled to a high labelling efficiency (998%) and specific activity (3515–
3700 MBq/mg) with retained biochemical integrity, stability and biological activity. Scintigraphy
with 99mTc-rituximab in patients showed a rapid and persistent spleen uptake, and the kidney
appeared to be a prominent source for the excretion of radioactivity. Inflamed joints showed a
variable degree of uptake at 6 h p.i. in patients with rheumatoid arthritis indicating patient
variability; similarly, the salivary and lacrimal glands showed variable uptake in patients with
Sjögren’s syndrome, Behçet’s disease and sarcoidosis. Inflammatory disease with particular
characteristics showed specific uptake in inflammatory lesions, such as, dermatopolymyositis
patients showed moderate to high skin uptake, a sarcoidosis patient showed moderate lung
uptake, a Behçet’s disease patient showed high oral mucosa uptake and a polychondritis patient
showed moderate uptake in neck cartilages. In one patient with systemic lupus erythematosus,
we did not find any non-physiological uptake.
Conclusion: Rituximab can be efficiently labelled with 99mTc with high labelling efficiency. The
results suggest that this technique might be used to assess B lymphocyte infiltration in affected
organs in patients with autoimmune diseases; this may provide a rationale for anti-CD20 therapies.
Key words: Rituximab, Anti-CD20 antibody, Radiolabelling, Molecular imaging, Therapy
decision making
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Introduction
Rheumatoid arthritis (RA), psoriatic arthritis (PsA),Sjögren’s syndrome (SS), systemic lupus erythemato-
sus (SLE), dermatopolymyositis, Behçet’s disease, sarcoid-
osis and polychondritis are chronic inﬂammatory
autoimmune diseases, and their treatment is often compli-
cated. It has been shown that targeting B cells can directly
alter autoimmune responses [1] in patients with these
diseases. In the last few decades, our knowledge about the
crucial role of B lymphocytes in disease pathogenesis has
been increased from the advancement made in the under-
standing of human immune system, including mechanisms
of lymphocyte activation and antigen processing, immune
tolerance, T and B lymphocytes crosstalk, and the role of
pro-inﬂammatory cytokines in autoimmune processes [2–6].
B cells are responsible for the production of auto-antibodies
and rheumatoid factor and are also involved in T cell
activation, pro-inﬂammatory cytokine production and there-
fore play an important role in the pathogenesis of inﬂam-
matory autoimmune diseases [7, 8]. These cells have been
found in pathological inﬁltrates in affected tissues of patients
with autoimmune diseases and are implicated in disease
progression [9]. The development of mature B cells from
stem cells involves several stages, each of which changes in
expression of a wide range of cell surface markers. Thus,
there are several potential candidates, on which B cell-
depleting therapies can act directly, via use of monoclonal
antibody (mAb) directed against cell surface markers (such
as CD19, CD20, CD22) [10, 11] or indirectly via blockade
of cytokine pathways (such as TNF-α, interleukin-6, B
lymphocyte stimulator (BLyS) and proliferation-inducing
ligand APRIL) [12]. CD20 is expressed on more than 95%
of B lymphocyte from blood and lymphoid organs, therefore
particularly suitable target for immunotherapy [7]. This
antigen expressed on the surface of B cell precursors,
mature B cells and B cell lymphomas, but is not expressed
on hemopoietic stem cells, pro-B cells, normal plasma cells,
dendritic cells and other normal tissues. Anti-CD20 therapies
include the humanized anti-CD20 mAbs ocrelizumab and
veltuzumab, and the fully human mAb ofatumumab. These
antibodies vary in the extent of humanization and have
different complement dependent cytotoxicity (CDC), and
antibody-dependent cell-mediated cellular cytotoxicity
(ADCC). Recently, TRU-015, a new anti-CD20 small
modular immunopharmaceutical protein (SMIP) has been
engineered, which is a dimeric, single-chain polypeptide
(approximately one third to one half the size of mAb), for
the treatment of RA and lymphoma [13, 14].
Rituximab (MabThera®; F. Hoffmann-La Roche Ltd.,
Switzerland/Rituxan®; Biogen IDEC Pharmaceuticals Inc.,
USA), is an IgG1κ isotype chimeric anti-CD20 mAb that
binds speciﬁcally to the transmembrane CD20 antigen.
Rituximab was the ﬁrst chimeric mAb approved by the
United States Food and Drug Administration in 1997 for the
treatment of malignancy, and in 2006 for the treatment of
patients with active RA, who do not respond to one or more
tumor necrosis factor (TNF) antagonist therapies. Rituximab
promote B cell lysis by CDC, ADCC and induction of
apoptosis.
The above data highlighted the opportunity to use the
radiolabelled anti-CD20 mAb probe for in vivo imaging of
CD20 positive B lymphocyte inﬁltration in inﬂammatory
lesions. Such a probe would also allow non-invasive
evaluation of disease extent and severity in patients affected
by autoimmune diseases thus allowing better staging of the
disease, since this might be difﬁcult to assess by other
conventional techniques [15]. This approach, moreover, may
allow to perform an ‘evidence-based biological therapy’
with a view to assessing whether the antibody will localize
in an inﬂammatory foci before using the same unlabelled
anti-CD20 for therapy. Since, biological therapies are
expensive and can be associated with severe side effects,
scintigraphy with radiolabelled rituximab might prove
particularly important for the selection of patients to be
treated with unlabelled rituximab and may also be useful in
patient follow-up for monitoring the efﬁcacy of therapy.
Materials and Methods
Antibody
Rituximab (MabThera®) was provided by F. Hoffmann-La Roche
Ltd., Switzerland.
Labelling of Rituximab with 99m-Technetium
Rituximab was labelled with 99m-technetium using a direct, 2-
mercapthoethanol (2-ME) reduction method, as previously de-
scribed [16]. Brieﬂy, disulﬁde bridges of the mAb were reduced by
incubating a molar excess of 2-ME with rituximab solution
(Mabthera®), for 30 min at room temperature in the dark. Different
molar ratios between 2-ME: mAb (1,000:1, 2,000:1 and 4,000:1)
were used in order to achieve the best activation of antibody and
consequently the highest labelling efﬁciency (LE). Before labelling,
activated antibody was puriﬁed by G-25 Sephadex PD10 desalting
columns (GE Healthcare) and N2 purged cold phosphate buffer
saline (pH 7.4) as eluant. After activation and puriﬁcation, the
antibody was aliquoted in 100 μg each vial, and stored at −80°C,
up to their use for radiolabelling.
Methylene diphosphonic acid (MDP) was used as weak trans-
chelating ligand. The bone scan kit (Osteocis®, CIS Bio Interna-
tional) containing 3 mg methylene diphosphonic acid, 0.45 mg
SnCl2.2H2O, 0.75 mg of ascorbic acid, 10.0 mg of sodium chloride
was reconstituted with 1 ml of N2 purged normal saline solution.
Different amounts (from 1 to 10 μl) of methylene-diposphonate
solution were tested with 100 μg of activated antibody and
370 MBq of 99mTcO4
− freshly eluted from a 99Mo/99mTc generator
in order to achieve the highest LE. In the preparation of the
radiopharmaceutical, all clinical grade reagents were used under
sterile conditions.
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Radiochemical Purity
Quality controls were performed using Instant Thin Layer Chro-
matography-Silica Gel (ITLC-SG) strips (VWR International). The
strips were analyzed on a radio-scanner (Bioscan Inc.) to quantitate
the percentage of activity bound to the mAb. When 0.9% NaCl was
used as the solvent (with normal ITLC-SG strips), retention factors
(Rf) were: 99mTc-rituximab=0.0; 99mTc-MDP and free 99mTcO4
−=
0.9–1.0, whereas elution of albumin absorbed ITLC-SG strips with
NH3/H2O/ethanol (1:5:2) resulted in Rf values of:
99mTc-colloids=
0.0; 99mTc-rituximab, and free 99mTcO4
−=0.9–1.0.
Stability
Stability of 99mTc-rituximab in human serum and normal saline was
measured up to 22 hours, in four replicates. Onemilliliter of fresh human
serum was added, in each of four aliquots of radiolabelled rituximab
(100 μg) and incubated at 37°C. In another four aliquots of radiolabelled
rituximab (100 μg), 1 ml of normal saline was added in each, was added
and incubated at room temperature. The percentage of free 99mTcO4
−
and radioactivity bound to mAb were measured at different time points
(1, 3, 6 and 22 h) by ITLC-SG (as described above).
A cysteine challenge assay was also performed to check the in vitro
stability of radiolabelled antibody at 37°C for 60 min, in four
replicates. 99mTc-rituximab was incubated at different molar ratios of
cysteine and mAb, ranging from 64:1 at the highest cysteine
concentration to zero in the absence of cysteine. At the end of the
incubation time, each reaction mixture was evaluated by ITLC-SG, as
described above. All known chemical forms of 99mTc-cysteine have Rf
values between 0.5 and 1.0, when normal saline is used as a eluent.
Structural Integrity
Possible modiﬁcations induced by 2-ME reduction procedure on
rituximab were tested by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) in non-reducing conditions. Equal
amount of protein (Native mAb, activated mAb and radiolabelled
mAb) in each lane (25 μg) were subjected to 8% SDS-PAGE, at
45 mA constant voltage, along with protein molecular weight
marker (11–250 kD, BioRad). After 2 h of electrophoresis, the gel
was stained with Coomassie brilliant blue G250 (Sigma-Aldrich)
for 60 min and washed thrice (15 min each) with a methanol/H2O/
acetic acid (4.5:4.5:1) solution.
Autoradiography of 99mTc-rituximab was also performed to check
the incorporation of radioactivity in mAb after radiolabelling. For this
purpose, radiolabelled mAb (11.1 MBq) was loaded in a separate lane
of SDS-PAGE. The gel was exposed to a Kodak® BioMax
photographic plate (Sigma-Aldrich) for 20 min, and the photographic
plate was developed subsequently by using Kodak® GBX developer/
replenisher (Sigma-Aldrich) and Kodak® GBX ﬁxer/replenisher
(Sigma-Aldrich) solutions, according to standard procedure.
Sterility
Radiolabelled mAb was sterilized by ﬁltration through 0.22 μm
Millipore GV syringe ﬁlter (low protein-binding ﬁlter) into a sterile
vial, under the aseptic condition. Sterility test was performed on
single-patient doses from three different batches, by direct
inoculation method using heamoculture vials, Plus+Anarobic/F
and Plus+Arobic/F (BD BACTECTM, BD Biosciences); these vials
were incubated at 37°C for 7 days.
In vitro competitive binding assay
To test the in vitro binding ability of 99mTc-labelled rituximab with
speciﬁc receptors, a competitive binding assay was performed on
CD20 positive, Burkitt lymphoma-derived cell line, RAJI [17]. The
cell were maintained in an RPMI 1640 culture medium (Sigma-
Aldrich) supplemented with 10% heat inactivated foetal calf serum
(Gibco), 1% L-glutamine (Gibco), 1% antibiotics (penicillin and
streptomycin, Gibco), at 37°C in a 5% CO2 humidiﬁed incubator.
Cell viability and cell count was determined by trypan blue assay
using a haemocytometer.
For binding experiment, 99mTc-rituximab at increasing concen-
trations (from 0.05 to 50 nM) were incubated in triplicate with 4×
105 cells alone or in the presence of 100 molar excess of the
unlabelled antibody to saturate the speciﬁc receptor on cells. After
2 h of incubation, cells harvested by centrifugation (9,000×g for
3 min) and washed two times with complete RPMI 1640 culture
medium. Cells and supernatants were collected in different vials
and were counted separately for radioactivity in a single-well
gamma counter (Gammatom s.p.a., Italy). The curve of speciﬁc
binding was generated as difference between total binding and non-
speciﬁc binding. A Scatchard analysis was performed by using
GraphPad Prism Version 5.00 Software (GraphPad Software, Inc.)
to determine the dissociation constant (Kd).
Immunoreactive Fraction Assay
The assay for determination of the fraction of immunoreactive
antibody by linear extrapolation to conditions representing inﬁnite
antigen excess has been adapted with slight modiﬁcations from the
method described by Lindmo et al. [18].
The immunoreactive fraction assay was performed using a constant
concentration of radiolabelled mAb and serial dilutions of RAJI cells.
The cells were washed three times in phosphate-buffered saline (pH
7.4) and suspended in a cold phosphate-buffered saline (PBS) with 1%
bovine serum albumin (BSA) solution. Radiolabelled mAb at a
constant concentration of 50 ng/ml, in PBSwith 1%BSA solution was
added to different amounts of cells (ﬁnal concentration ranging from
2.6×106 to 0.08×106 cells/ml). Cells were incubated for 2 h at 4°C and
then washed twice with 500 μl of cold PBS with 1% BSA solution,
before counting cell-associated radioactivity in a single-well gamma
counter. The data were plotted as a double inverse plot of the applied
radiolabelled antibody over the speciﬁc binding as a function of the
inverse cell concentration. In this plot, the origin of the abscissa
represents inﬁnite cell concentration, i.e., conditions of inﬁnite antigen
excess. All experiments were performed in duplicate.
Patients
We studied 20 consecutive patients (M/F, 4/16; mean age, 55.5±
11.65 years; mean disease duration, 12±99.3 months) who met
with our inclusion criteria (stated below) and referred to the
outpatient clinic of the rheumatology unit of ‘Sapienza’ University
G. Malviya, et al.: 99mTc-rituximab for B Cell Imaging 639
of Rome (Italy) due to chronic inﬂammatory autoimmune diseases,
including RA, PsA, dermatopolymyositis, sarcoidosis, Sjögren’s
syndrome, SLE, Behçet’s disease and polychondritis (n=5, 3, 5, 2,
2, 1, 1 and 1, respectively). All patients agreed to participate in the
study and signed a written informed consent. None of the enrolled
patient received unlabelled rituximab therapy before the study.
Inclusion criteria for patients were different depending on the
type of pathology. RA: a moderate/high disease activity evaluated
by a disease activity score (DAS) on 44 joints 93.7 [19], despite a
treatment with disease-modifying anti-rheumatic drugs (DMARDs),
including methotrexate at adequate dose and the failure of at least
one TNF-α-blocker drug; all RA patients were candidates for a
second level therapy as an anti-CD20 monoclonal antibody. PsA: a
moderate/high disease activity evaluated by the swollen and tender
joints count, patient and physician global assessment, despite a
treatment with DMARDs and TNF-α blockers. Dermatopolymyo-
sitis: patients with an insufﬁcient response to corticosteroids to
commonly used immunosuppressants (azathioprine, mycopheno-
late, methotrexate or cyclosporine) or to high dose i.v. immuno-
globulins, documented by clinical evaluation and altered laboratory
tests. Sarcoidosis: a resistant disease to steroids, immunosuppres-
sive drugs and/or antimalarial therapies. Sjögren’s syndrome: an
active disease, resistant to substitute agents for sicca features,
glucocorticoids and immunosuppressive agents for extra-glandular
involvement. SLE: a moderate/severe disease activity evaluated by
the systemic lupus erythematosus disease activity index (SLEDAI)
[20] despite standard doses of steroid and immunosuppressive
therapy. Behçet’s disease: an active disease, resistant to standard
treatment including immunosuppressive agents such as azathioprine
and cyclosporine in combination with corticosteroids and colchi-
cine. Polychondritis: a poorly controlled disease, despite non-
steroidal anti-inﬂammatory drugs, immunosuppressants (particularly
methotrexate) or steroids.
Clinical assessment
Patients were evaluated by the same rheumatologist, and data were
collected into a standardized case record forms, which included
demographics, diagnosis, date of diagnosis, comorbidities, past and
present treatments, biological therapies if prescribed, the start of the
treatment and concomitant medications. Diagnosis of all mentioned
diseases (RA, PsA, dermatopolymyositis, sarcoidosis, Sjögren’s
syndrome, SLE, Behçet’s disease and polychondritis) were formu-
lated according to international classiﬁcation criteria for each illness
[21–28].
Non-speciﬁc and speciﬁc laboratory tests, including erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), muscle
enzymes, immunological analysis such as Anti-nuclear antibodies
(ANA), extractable nuclear antigens (ENA) proﬁle, rheumatoid
factor, anti-citrullinated peptide antibodies and human leukocyte
antigen (HLA)-B51 detection (only for Behçet’s patient) were
performed. When necessary, patients underwent other imaging
procedures, such as chest radiography, computed tomography (CT)
of chest, functional pulmonary tests and bronchoalveolar lavage
(BAL) for sarcoidosis; ostheo-articular ultrasonography (US) or
magnetic resonance imaging (MRI) for RA and PsA; salivary
glands US for Sjögren’s syndrome; and muscles MRI for
dermatopolymyositis .
Clinical evaluation in arthritis (RA and PsA) patients included
count of swollen and tender joints, patient and physician global
assessment (visual analog scale, VAS). Overall disease activity was
also measured for RA patients with the DAS 44 which takes in
consideration pain and swollen in 44 joints.
A biopsy for tissues of interest, such as dermal, muscular and
salivary gland was performed in dermatopolymyositis and Sjögren’s
syndrome patients.
Scintigraphic Studies with 99mTc-Rituximab
All patients underwent immunoscintigraphy, before treatment with
unlabelled rituximab, to assess uptake of 99mTc-rituximab in the
inﬂammatory lesions. Anterior planar whole body images were
acquired 6 and 20 hours after i.v. administration of 350–370 MBq
(100 μg) of 99mTc-rituximab. Planar anterior and posterior images of
affected sites were also acquired at 6 and 20 hours. Images were
acquired with a Philips Sky-Light dual head gamma camera ﬁtted with
a high resolution collimator. Whole body planar images were acquired
on 256×1024 pixel matrix at 10 cm/min (at 6 h) or 5 cm/min (at 20 h)
scanning speed. “Static regional images” were acquired on 512 x 512
pixel matrix for 300 seconds (at 6 h) or 600 seconds (at 20 h). A time-
mode, rather than a count-mode acquisition modality was chosen to be
able to compare images of different patients, being injected with
almost the same dose of radioactivity, thus avoiding operator bias in
image acquisition and analysis.
The scintigraphic scans were interpreted by two experienced
nuclear medicine physicians. The interpreters had clinical informa-
tion obtained from the patient’s referring physician but no
information on the other imaging modality. Nevertheless, the
uptake interpretation were describe as mild, moderate and high
comparing with the heart and large blood vessel activity. An uptake
was considered as ‘mild’ when it was lower than heart and large
blood vessel uptake, ‘moderate’ when it was equal to heart and
large blood vessel uptake, and ‘high’ when it was higher than heart
and large blood vessel uptake.
Statistical analysis
The student t-test was used to compare quantitative variables in the




By using a direct labelling method, the best results were
obtained when disulﬁde bridges of the antibody were
reduced using a 2,000-fold excess of 2-ME. An increase in
2-ME concentration for reduction of rituximab, results in
decreased LE, and higher colloid percentage. We obtained a
high LE (998%) with negligible amount of colloids (G2%)
with high speciﬁc activity (3,515–3,700 MBq/mg), when the
activated mAb was labelled with 99mTc by using only 3 μl of
methylene diphosphonic acid solution (from the bone scan
kit). Thus, a post labelling puriﬁcation step could be
avoided.
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Stability
Radiolabelled rituximab was stable when incubated in
fresh human serum or in normal saline up to 22 h, as
shown in Fig. 1a. After 22 h, still more than 80% of the
radioactivity was bound to the antibody in both media.
The results of cysteine challenge assay also demonstrated
that radiolabelled rituximab was stable, approximately
95% intact when exposed to up to a 16-fold excess of
cysteine (Fig. 1b).
Structural Integrity
SDS-PAGE analysis of native, activated and radiola-
belled rituximab show, one thick band of 145 kilodalton
(kDa) in native rituximab lane; bands of different
molecular weights in activated rituximab lane probably
due to light/heavy chain complexes after 2-ME reduction;
whereas, mainly one thick band of approximately
145 kDa in radiolabelled rituximab lane, i.e., the
molecular weight of intact mAb (Fig. 2). Autoradiogra-
phy of 99mTc-rituximab lane, showed that almost all
radioactivity was attached with the band of higher
molecular weight (145 kDa).
Fig. 1. a Stability of 99mTc-rituximab in saline and in plasma
assessed by ITLC-SG at different time points. b Cysteine
challenge assay of 99mTc-rituximab assessed by ITLC-SG at
increasing ratio between cysteine to mAb.
Fig. 2. SDS-PAGE analysis performed in non-reducing
condition showing native, activated and 99mTc labelled
rituximab lane. The autoradiography analysis (first lane)
showing radioactivity associated with the band of complete
mAb (145 kDa).
Fig. 3. Saturation binding curve of 99mTc-labelled rituximab
to RAJI cells. Kd for 99mTc-rituximab 8.3 nM. Curve fitting
was performed using GraphPad software.
Fig. 4. A double inverse plot of the immunoreactivity
fraction assay was used to determine immunoreactive
fraction (i.e., 85.5%).
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Sterility
The sterility test did not show any Gram+ve or –ve bacterial
growth in heamoculture vials inoculated with 99mTc labelled
rituximab.
In vitro competitive binding assay
The saturation binding curve was plotted as a speciﬁc bound
radioactivity against increasing molar concentration of
radiolabelled mAb showed a plateau (Fig. 3). A 100-fold
molar excess of unlabelled antibody saturates the receptors
present on cells, and consequently prevented the speciﬁc
binding of the radiolabelled rituximab, which shows that
rituximab retained its speciﬁc binding activity with CD20
receptors expressed on RAJI cells, even after the radio-
labelling with technetium-99 m. Kd for 99mTc-rituximab 8.3
nM, which is only slightly higher than the Kd of native
rituximab, i.e., 5.2 nM.
Immunoreactive Fraction Assay
The data demonstrate a very close linear relationship of
‘total applied/ speciﬁc binding’ as a function of the inverse
cell concentration. Fitting of a straight line to the data by
means of linear regression analysis allows an easy and
precise determination of the intercept value at the ordinate.
This value equals 1/immunoreactive fraction; thus in this
case, the immunoreactive fraction was 85.5%, as indicated in
the Fig. 4.
Clinical Assessment
In clinical evaluation, all RA patients had moderate pain,
and swelling and/or tenderness in knees and wrists, ankles,
shoulders. VAS was 75±11.2, ESR was 29±22, CRP was
0.55±13.4, DAS 44 was 4.9±1.1. PsA patients had a mean
ESR of 35±31 and CRP of 0.8±2.2; they also showed
moderate pain and swelling and/or tenderness in the knees,
wrists, ankles and shoulders.
The ESR (millimeters per hour) and CRP (milli-
grammes per liter) values, evaluated before the scan of
patients with dermatopolymyositis, Sjögren’s syndrome,
sarcoidosis, SLE, Behçet’s disease and polychondritis are
shown in Table 1. Additionally, patients with dermato-
polymyositis and Sjögren’s syndrome had positive biop-
sies, and both Sjögren’s syndrome patients were reported
positive for ultrasonography (US) of the salivary glands.
Moreover, both sarcoidosis patients had a positive BAL,
and an oral aphtosis was noticed in Behçet’s disease
patient conﬁrming the disease.
Scintigraphic Studies with 99mTc-Rituximab
After i.v. administration of 99mTc-rituximab (350–370 MBq;
100 μg), the whole body images were acquired at 6 and
20 h. We observed a mild to moderate to high uptake in the
Fig. 5. Whole body scintigraphic images at 6 h with 99mTc-rituximab in patients with a dermatopolymyositis (see skin uptake).
b Rheumatoid arthritis (see joint uptake). c Sjögren’s syndrome (see salivary and lacrimal gland uptake). d Behçet’s disease (see
oral mucosa uptake). e Sarcoidosis (see lung uptake).
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affected regions at 6 h p.i., in all the patients with different
autoimmune diseases (Fig. 5a–e and Table 1). At 20 h, we
found a low background activity and consequently higher
target to background (T/B) ratio.
In the ﬁve patients with active RA and the three patients
with PsA, we observed an uptake of the radiopharmaceutical
in the known affected joints (including knees, wrists,
elbows, phalanges, ankles and shoulders). This uptake was
variable and not every patient did show uptake in each
clinically affected joint(s) (Fig. 6a).
Muscle and skin uptake in patients with dermatopolymyo-
sitis were detected; however, this kind of scintigraphy was
more positive at 20 h when the background blood pool activity
was decreased. Interestingly, in one dermatopolymyositis
patient we found a very mild spleen uptake, in contrast to the
high uptake normally present in all other subjects. After that,
FACS analysis of peripheral blood cells conﬁrmed the presence
of a signiﬁcantly low B lymphocyte count in this patient.
Patients suffering from Sjögren’s disease showed a
variable 99mTc-rituximab uptake in salivary and moderate
uptake lachrymal glands (Fig. 6b).
Scintigraphy in the patient with Behçet’s disease demon-
strated clearly detectable buccal 99mTc-rituximab activity at
6 h p.i. (Fig. 6c).
We also performed scintigraphic examination in one
patient with sarcoidosis in which a mild 99mTc-rituximab
uptake was found in the nasal cavity, salivary and lachrymal
glands (Fig. 6d) similar to the so-called “Panda Sign”
described for scintigraphy with 67Ga-citrate [29]. However,
we could not see a high uptake in the lung region, as per our
expectation.
An SLE patient was difﬁcult to evaluate. We found a mild
radiopharmaceutical uptake in the lung region. This patient did
not show uptake in clinically deﬁned inﬂammatory lesions.
The patient with polychondritis showed an abnormal
radiopharmaceutical uptake in the cartilages of the neck
(thyroid and cricoid cartilages) and in a regional lymph
node. Some faint uptake was also detectable in the sub-
mandibular salivary glands.
A variable thyroid uptake was detected in ten out of 20
patients (50%). We therefore wanted to investigate whether
there was an autoimmune reaction in these patients and we
asked them to test anti-thyroglobulin (anti-Tg) and anti-
thyroid peroxidase antibody (anti-TPO). Interestingly, ﬁve
of these patients showed increased anti-thyroid auto-anti-
bodies, whereas amongst the ten patients without thyroid
uptake of 99mTc-rituximab, none had increased anti-thyroid
auto-antibodies.
None of the patients showed any kind of side effect,
adverse event or other type of reaction following the
administration of the radiotracer used, either immediately
after injection or after 1 month.
Discussion
Previous studies with radiolabelled non-speciﬁc probes
(such as 99mTc-human polyclonal immunoglobulins, 67Ga-
citrate, 99mTc-albumin nanocolloids, 18F-FDG, 99mTc- and
111In- labelled liposomes) were focused on the detection of
the state of activity of the disease [30, 31]. Nevertheless, no
real clinical advantages have been proved comparing this
radiopharmaceuticals to other available diagnostic techni-
ques (such as ultrasonography, X-ray, magnetic resonance
imaging) with regard to the clinical management of patients.
The real breakthrough in targeted immunoscintigraphy for
inﬂammatory disease patients is the possibility to highlight
the presence of the relevant receptors involved in the
pathophysiology of the disease directly by means of the
Fig. 6. Static regional scintigraphic images with 99mTc-rituximab in patients with a Rheumatoid arthritis (at i 6 h and ii 20 h). b
Sjögren’s syndrome (at 6 h). c Behçet’s disease (at 6 h). d Sarcoidosis (at 6 h).
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speciﬁc radiolabelled mAbs that will eventually be used for
treatment. Some radiolabelled mAbs (such as anti-E-selectin
and anti-CD4) demonstrated their excellent capability for the
localization of inﬂammatory regions, but lack of their use for
the therapeutic purposes, thus limiting their further develop-
ment and use for immunoscintigraphy. However, approval
of mAbs for therapeutic purposes (such as anti-CD20 for
treatment of rheumatic patients) provides us an opportunity
to select the patients through this technique.
In the present study, we aimed to radiolabel rituximab
with 99mTc for scintigraphic studies, and then, as a proof of
concept, we evaluated its in vivo localisation pattern in a
cohort of patients affected by different autoimmune diseases.
The results obtained so far are highly encouraging and hold
promise for therapy decision making and follow-up, with a
view to assessing whether an antibody will accumulate in an
inﬂamed tissue before using the same unlabelled antibody
for therapeutic purposes. This kind of information can only
be obtained with such kind of imaging approach based on
new radiopharmaceuticals that provide a solid basis for the
further development and clinical use of immunoscintigraphy
in inﬂammatory autoimmune disease patients.
We demonstrated that rituximab could be labelled with
99mTc without any modiﬁcation in its biological activity and
speciﬁcity for CD20 receptors in vivo. Direct radiolabelling
method using 2-ME reduction of antibody, is simple, rapid,
reliable and yielding high LE with excellent in vivo
targeting. We always labelled antibody to a high labelling
efﬁciency (998%) and speciﬁc activity (3,515–3,700MBq/mg).
SDS-PAGE and autoradiography analysis demonstrated that the
radioactivity stands with whole antibody molecule (band of 145
kD). Our immunoreactive fraction assay demonstrated that
85.5% of the antibody was immunoreactive even after the
radiolabelling procedure.
For scintigraphic studies, we injected a tracer dose of
350–370 MBq (100 μg) of rituximab, which is a much lower
dose in comparison with therapeutic dose (with no adverse
or allergic reaction) that is unlikely to alter the natural
history of the disease or have any therapeutical effect.
In patients, at 6-h images, 99mTc-rituximab was detectable
in the heart and large vessels, liver, spleen and kidneys with
more variable uptake in the lungs, thyroid and bone marrow.
Rapid and persistent uptake of the spleen was also concordant
with results recently published by Stopar et al. in patients with
B cell non-Hodgkin’s lymphoma [32]. At 20-h images, we
observed reduction of blood pool activity and lung activity with
increased liver and spleen activity. Bowel activity was never
detected. Thyroid and salivary gland uptake was not always
concordant, and stomach uptake was never detected. Thyroid
uptake could be correlated to the presence of subclinical
autoimmune phenomena in this organ, since the presence of
anti-thyroid auto-antibodies in ﬁve out of ten patients with
thyroid uptake. In the remaining ﬁve patients (with thyroid
uptake but without anti-thyroid auto-antibodies) we cannot
exclude the presence of a “silent” lymphocyte inﬁltration as
well as possible uptake of free Tc, the latter possibility being,
however, unlikely because of the absence of salivary gland
uptake in these patients.
The use of radiolabelled mAbs against lymphocyte
antigens for therapy decision making was already exlplored
by us with success and clinical beneﬁt. The most clinically
relevant example is the immunoscintigraphy with 99mTc-
anti-TNF-α mAb in Crohn’s disease (CD) and RA patients
[16, 33]. In the ﬁrst study in CD patients, 99mTc-inﬂiximab
(a commercially available mAb anti-TNF-α) showed uptake
in the affected bowel only in few patients that responded to
anti-TNF treatment [16]. In another study in patients with
active RA before intra-articular treatment with inﬂiximab,
we observed a variable degree of joint uptake that did not
correlate with swelling or pain of the joint, but could predict
the success of therapy [33]. These studies demonstrated that
radiolabelled anti-TNF-α scintigraphy could be useful for
improving the selection of those patients who could beneﬁt
most from therapy with TNF-α antagonists, an example of
the use of immunoscintigraphy for therapy decision making.
In line with this strategy, in the present study, scintigraphic
images with 99mTc-rituximab demonstrated moderate to high
accumulation in some affected joints of arthritis patients, but
some other swelling and painful joints were negative at the
scan. This suggests that not all joints have a similar pattern
of B lymphocyte inﬁltration and, therefore, the total-body
evaluation of CD20 positivity should be mandatory before
initiating anti-CD20 therapy. Overall, our data demonstrated
different biodistribution of radiolabelled CD20 in different
patients, thus different degrees of B lymphocyte inﬁltration
in different tissues of different patients. Our results are
encouraging and hold promise not only for imaging of B
lymphocyte inﬁltration in inﬂammatory diseases but, most
importantly, for mapping B lymphocytes in affected tissues
of each patient in order to establish a personalized therapy.
Despite large prospective studies being required to
conﬁrm the clinical utility of this technique in each disease,
data obtained so far indicate that the information about the
presence of drug targets for personalised therapy, by means
of immunoscintigrapy, is of great clinical and social
relevance for optimizing treatments, avoiding unnecessary
therapies and reducing costs thus providing a cost-effective
solution for biological therapies.
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